A History of Innovation
As an industry pioneer, Siemens Healthcare makes an astounding investment in research and development, over one billion Euros annually, to bring real-world solutions to healthcare providers.
Since 1896, when Siemens invented the first industrially manufactured X-ray
tubes for medical diagnostics, we have engineered answers that have become instrumental to the health of patients and the organizations that care for them.
- Comprehensive imaging solution that combines reliable radiopharmaceutical manufacturing and distribution with innovative PET hardware and software1 for PET imaging of amyloid plaques – one of the necessary pathological features of Alzheimer’s disease2,3,4 – in the living brain.
- Wireless transducer ultrasound system.
- Fully integrated positron emission tomography (PET) and magnetic resonance (MR) system.
- PET-CT scanner.
- Dual source CT.
- Angiography C-arm system based on robotic technology.
- Blood test for measuring circulating levels of the HER-2/neu oncoprotein.
- Automated equimolar Vitamin D Total Assay with 18-minute results.
- hsCRP test indicated for cardiovascular risk assessment and risk stratification.
- Workflow-enabled Healthcare Information System (HIS).
Facts and Figures
Siemens innovative technologies are instrumental to the health of organizations and patients in the U.S. and throughout the world.
- Our products are found in 8 out of 10 U.S. hospitals.
- All 17 hospitals on U.S. News & World Report’s 2012 Best Hospitals Honor Roll use Siemens solutions.
- Over 9 billion diagnostic tests sold worldwide, reaching over 800 million patients per year with chemistry and immunoassay tests alone.
- Over 220 million healthcare information transactions are processed daily by our 24/7/365 Healthcare Computing Center.
View our history of firsts throughout the years.
1syngo.PET Amyloid Plaque is intended for use only with approved amyloid radiopharmaceuticals in the country of use. Users should review the drug labeling for approved uses.
2Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging–Alzheimer‘s Association Guidelines for the Neuropathologic Assessment of Alzheimer‘s Disease. Alzheimers Dement. 2012;8:1-13.
3Mirra SS, Heyman A, McKeel D, et al; and participating CERAD neuropathologists. The Consortium to Establish a Registry for Alzheimer‘s Disease (CERAD): Part II:
Standardization of the Neuropathologic Assessment of Alzheimer‘s Disease. Neurology. 1991;41(4):479-486.
4Thies W, Bleiler L; Alzheimer‘s Association. Alzheimer‘s Association Report: 2012 Alzheimer‘s Disease Facts and Figures. Alzheimers Dement. 2012;8:131-168.